Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252510 | 0.93 | MEN1 (0.47) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL31683420 | 0.91 | MEN1 (0.46) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL13455405 | 0.88 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6714850 | 0.88 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL17324108 | 0.87 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL18483726 | 0.87 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL13301296 | 0.86 | EPHX2 (0.33) | ALDH1A1 | |
| SCHEMBL2627782 | 0.86 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL20129268 | 0.86 | MEN1 (0.45) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL1626948 | 0.84 | ALDH1A1 (0.46) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970303-B9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-8426477-B1 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8263665-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263663-B2 | Azide functionalized peptide targeting groups | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8258190-B2 | Encapsulated contrast agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8143271-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091534-A1 | COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100081825-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100081825-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2010-04-01 | — | — | US | disclosed |
| US-7638558-B2 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7618944-B2 | Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7163776-B2 | Positive-working resist composition | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| WO-2002032963-A1 | IMMUNOADJUVANT SYSTEMS | ALCHEMIA PTY LTD (AU) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | MEN1 227/4885KMT2A 4844/4885KDM4C 4846/4885 |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MEN1 1452/4885KMT2A 1133/4885KDM4C 3360/4885 |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | IAPP, NGLY1, MSN | MEN1 340/4885KMT2A 4444/4885KDM4C 4458/4885 |
| US-20110091534-A1 | COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, ABCB11, CLTB | MEN1 921/4885KMT2A 4747/4885KDM4C 3499/4885 |
| US-20100081825-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | MCHR1, MCHR2, MC5R | MEN1 1012/4885KMT2A 2330/4885KDM4C 4538/4885 |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | MEN1 161/4885KMT2A 4044/4885KDM4C 3322/4885 |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | MEN1 920/4885KMT2A 4479/4885KDM4C 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.